Cell-free DNA Analysis in Liquid Biopsy: A New Paradigm for Machine Learning-Driven Cancer Diagnosis

cfDNA is extracellular DNA fragments in the blood circulation, derived from normal cell metabolic release, apoptotic/necrotic cells, circulating tumor cells, and tumor lysis. In cancer patients, tumor-derived cfDNA (ctDNA) carries tumor genetic and epigenetic information. Its biological characteristics include: fragmentation (160-180 bp, corresponding to nucleosome units), short half-life (1-2 hours, reflecting real-time status), systemic representativeness (overcoming the spatial limitations of tissue biopsy), and minimally invasive acquisition (venous blood sampling allows frequent monitoring).

Nucleosome Positioning and Epigenetic Features: Nucleosome positioning information can be obtained through fragment size distribution, end position, and coverage patterns; DNA methylation features include global hypomethylation (genomic instability), promoter hypermethylation (tumor suppressor gene silencing), and tissue-specific patterns (tracing origin); repetitive sequences have values such as high copy number, epigenetic regulation changes, and tissue-specific expression.

Machine Learning Applications: Feature engineering covers fragmentomics, methylation, copy number variation, and mutation features; models include supervised learning (classification such as random forests), unsupervised learning (clustering, etc.), and deep learning (CNN/RNN, etc.); multi-omics integration includes multi-modal, longitudinal data, and clinical data fusion.

Lung Cancer: Early detection (mutation/methylation features earlier than imaging); subtype differentiation (small cell/non-small cell) to guide treatment; treatment monitoring (changes in cfDNA levels reflect response).

Colorectal Cancer: SEPT9 methylation marker approved for screening; post-operative monitoring to predict recurrence; drug-resistant mutations to guide treatment adjustment.

Pancreatic Cancer: Screening of high-risk populations for early detection; distinguishing benign from malignant; prognosis evaluation to guide treatment intensity.

Glioblastoma: Blood-brain barrier limits blood ctDNA levels; cerebrospinal fluid analysis is more effective; treatment monitoring of molecular changes.

Pan-Cancer Detection: Multi-cancer early detection (MCED); tissue of origin tracing (inferring primary site via methylation patterns); integrating into routine physical examination for population screening.

Sensitivity and Specificity: Enhance low-frequency mutation detection capability through enrichment technologies (size selection, methylation sorting), ultra-high depth sequencing, and molecular barcode error correction.

Standardization and Quality Control: Unify sample collection and processing procedures, evaluate differences between detection platforms, and establish standardized bioinformatics workflows.

Clinical Validation: Need large-scale cohort studies to validate performance, prospective trials to evaluate impact on clinical outcomes, and health economics assessments to support medical insurance decisions.

Technological Development: Single-molecule sequencing (long-read information), proteomics integration (complementary markers), exosome analysis (DNA/RNA complementarity), microfluidic platforms (high-throughput and low-cost).

Clinical Prospects: Routine cancer screening, real-time treatment guidance, minimal residual disease detection, early recurrence monitoring.

Summary: cfDNA liquid biopsy combined with machine learning is a key tool in precision medicine, which will improve the quality of life of cancer patients and open a new era of cancer management.